CC4 Cost-Benefit Analysis of Recombinant Erythropoietin in Premature Neonates  by Wandstrat, TL & Maxwell, SR
Abstracts
CONCLUSIONS: Many ADES seen in ED patients are
preventable and contribute substantially to hospital costs.
At a time when much emphasis is put on the limitation of
health expenses, here is a domain where expense-cutting
could probably be done reasonably easily, while increas-
ing quality of care.
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Assessing the economic impact of medication side effects
is critical for the accurate determination of the cost-effec-
tiveness of pharmaceuticals. It is often necessary to em-
ploy modeling techniques that utilize incidence rates that
are based on the literature.
OBJECTIVE: To present a calculation of the cost of ste-
roid-induced side effects in renal transplantation as an
example of a literature-based model and to discuss the as-
sumptions, techniques, and difficulties inherent in the
methodology.
METHODS: We estimated the incidence of adverse
events associated with steroids using evidence-based liter-
ature analyses. This evidence was used to construct a
Markov cost model for each side effect. Side effects in-
cluded in the analysis were hypertension (and its compli-
cations), post-transplant diabetes mellitus (PTDM), pe-
ripheral bone fractures, osteonecrosis of the hip, and
cataracts.
RESULTS: The side effect incidences reported in the liter-
ature vary, in part due to different definitions and follow-
up periods. Furthermore, data from randomized con-
trolled trials can be handicapped by low statistical power
to detect side effects and patient crossover or dropouts.
Confounding and bias are concerns in case-control and
cohort studies, and can complicate the determination of
attributable risk from cohort studies. Utilizing the inci-
dence data from the literature, the total 10-year dis-
counted cost for a 50-patient cohort was $266,000.
CONCLUSIONS: Extracting side effect incidence data
from the literature is a challenging but essential step in
modeling side effect costs. The variability in reported re-
sults should be ascertained, and assumptions requiring
clinical expertise are often required. We have demon-
strated the methodology and estimated the financial cost
of adverse events associated with steroids in renal trans-
plantation.
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The use of recombinant human erythropoietin (rhEPO)
and intravenous (IV) iron was studied in a group of pre-
mature neonates.
OBJECTIVE: The study purpose was to conduct a cost-
benefit analysis of the use of rhEPO and IV iron to reduce
the need of erythrocyte transfusions (Ets) in premature
neonates.
METHODS: Neonates 24-30 weeks gestational age (GA)
were considered for admission into the study. Patients
were excluded if severe hemolytic or hepatic disease, or
renal failure were present. If caretakers did not consent to
rhEPO and IV iron therapy, the patients were followed as
controls. For patients who were given caretaker consent,
treatment included IV iron 1 mg/kg/day in hyperalimen-
tion or IV fluids and 400 U/kg/dose of IV rhEPO three
times per week for 4 weeks, initiated at days 1-5 of life.
There were 41 patients in the rhEPO group and 13 in the
control group recruited over 12 months.
RESULTS: The mean number of Ets performed in the
first 4 weeks of life were 2.8 ::'::: 2.5 for the control group
and 1.9 ::'::: 2.7 for the rhEPO group (p = 0.28). The direct
cost of providing rhEPO and IV iron to the 41 study pa-
tients was $8160.11 The direct cost of one Et in our insti-
tution is $235.05. No indirect costs (adverse effects) were
noted. The average reduction in Ets per patient was 0.9
and if extrapolated to 41 patients would have resulted in
cost savings (benefit) of $8673.34. The benefit to cost ra-
tio of this program was 1.1:1.
CONCLUSION: rhEPO and IV iron use was associated
with a reduction of Ets and proved cost beneficial in a
small group of premature neonates ~30 weeks GA.
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Apligraf'>' is a full thickness manufactured living skin
equivalent indicated for the treatment of venous leg ul-
cers (VLU).
OBJECTIVE: To undertake a model-based retrospective
cost-effectiveness analysis (CEA), from a societal and
health care perspective, of the outpatient treatment of
VLU with the 4-1ayer high-compression bandage system
with and without one application of Apligraf'?".
METHODS: Because no prospective head-to-head study
of this comparison had yet been undertaken, a computer-
based model was developed. The model represented the
clinical consequences of the two approaches (ulcers
healed, time to heal, ulcer recurrence, infections, compli-
